Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03970447 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by Global Coalition for Adaptive Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,280
- Enrollment target
- 20
- Study locations
NCT03970447: Recruiting Phase 2 study of Glioblastoma, sponsored by Global Coalition for Adaptive Research.
NCT03970447 is a Phase 2 study of Glioblastoma that is actively recruiting participants, run by Global Coalition for Adaptive Research. The registered enrollment target is 1,280 participants, above the 102-participant average among 199 other Glioblastoma trials with a reported enrollment target (1155% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03970447, a Phase 2 study of Glioblastoma, is actively recruiting participants, sponsored by Global Coalition for Adaptive Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,280 participants
- Enrollment target
- 20
- Study locations
Study Summary
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Primary Outcome
Overall survival is defined from the time of randomization to death from any cause. Patients still alive at the time of an analysis will be considered censored at their date of last contact.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Regorafenib
- RADIATION Radiation
- DRUG Lomustine
- DRUG Paxalisib
Study Locations (20)
California
- University of California, San Diego - La Jolla
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute - Los Angeles
- University of California, Los Angeles - Los Angeles
- St. Joseph Hospital - Orange
- University of California, San Francisco - San Francisco
- Stanford Cancer Center - Stanford
Florida
- Mayo Clinic Cancer Center - Jacksonville
- Sylvester Comprehensive Cancer Center - Miami
- Moffitt Cancer Center - Tampa
Georgia
- Piedmont Atlanta Hospital - Atlanta
- Winship Cancer Institute of Emory University - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Minnesota
- Abbott Northwestern Hospital - Minneapolis
- Mayo Clinic Cancer Center - Rochester - Rochester
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- University of Colorado Denver - Aurora
Connecticut
- Yale Cancer Center / Smilow Cancer Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,280 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2030-06 |
| Phase | Phase 2 |
What NCT03970447 shows while recruiting
NCT03970447 is an interventional study that assigns participants to a tested intervention. Its 1,280 participants enrollment target places it among the larger protocols in the corpus, above the 102-participant average among 199 other Glioblastoma trials with a reported enrollment target (1155% higher).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Temozolomide is the first listed.
NCT03970447 names 20 study sites across 10 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT03970447 about?
NCT03970447 is a clinical study titled "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma". Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
What is the current status of trial NCT03970447?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,280 participants. The study started on 2019-07-30. Estimated completion is 2030-06.
What conditions does trial NCT03970447 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT03970447?
The interventions under investigation include: Temozolomide (DRUG), Regorafenib (DRUG), Radiation (RADIATION), Lomustine (DRUG), Paxalisib (DRUG).
Who is sponsoring clinical trial NCT03970447?
This trial is sponsored by Global Coalition for Adaptive Research, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03970447 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03970447's enrollment target sits among peer trials
1,280 1st of 199 higher than 199 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
-
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT07207811 · 1,280 participants · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT07001800 · 1,276 participants · Phase 2
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI